A patient's self-reported data can be incomplete or biased, as they may only report the "good measures." To get the full picture, companies must gather input from multiple sources, like caregivers and clinicians. Each perspective helps correct the others, creating a more accurate and holistic view of the patient's journey.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Initial adoption of senior care technology was slow due to a resistant demographic. However, the market reached a tipping point driven by external crises: the system is burdened, care is unaffordable, and professional caregivers are scarce. This system failure now compels families to adopt technology out of necessity, not just preference.

While the 65+ population is growing, the 85+ cohort is projected to double by 2040. This specific, "care-intensive" group represents the core addressable market for senior services. Businesses focused on this niche benefit from a rapidly expanding customer base with high, non-discretionary spending needs.

A successful marketing strategy requires understanding the entire purchasing ecosystem, not just the final decision-maker. For a medical device, the procurement officer might sign the check, but the head of nursing who uses the product daily is the key influencer whose pain points must be addressed.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

MedTech companies often focus on pitching their solution's features. A more effective strategy for gaining trust and adoption is to first demonstrate a deep understanding of the user's (clinician, patient, admin) specific problems and pain points. This builds credibility and makes the solution itself more believable.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Family members are often thrust into the caregiver role with no formal training on the disease, treatment side effects, or how to provide emotional support. This highlights a critical need for structured educational resources to help caregivers cope and improve patient outcomes.